U.S. License Holder:
Regeneron Pharmaceuticals
Date of License:
August-18-2023
Last Update:
Sep-30-2024
FDA-Approved Indications
VEOPOZ (pozelimab-bbfg) is a complement inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.